Patents by Inventor Constantinos Panousis

Constantinos Panousis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALLELE SPECIFIC PCR ASSAY FOR DETECTION OF NUCLEOTIDE VARIANTS
    Publication number: 20160258010
    Abstract: Described herein are improved methods for detecting one or more alleles of a target nucleic acid molecule in a biological sample. The methods can be used, for example, for detecting low-frequency drug resistance mutations of a target nucleic acid molecule in a biological sample from a subject receiving the drug. In several embodiments, the subject is a subject with an HIV-1 infection, and the method is a method of detecting one or more drug-resistance mutations in an HIV-1 reverse transcriptase gene. Oligonucleotide primers for use in the disclosed methods, and compositions comprising same, are also provided.
    Type: Application
    Filed: October 20, 2014
    Publication date: September 8, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Constantinos Panousis, Elias Halvas, John Mellors
  • Anthranilic acid derivatives
    Patent number: 7989657
    Abstract: The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: August 2, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole A Kratochwil, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters
  • Novel Anthranilic Acid Derivatives
    Publication number: 20090247637
    Abstract: The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: June 3, 2009
    Publication date: October 1, 2009
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole A. Kratochwil, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters
  • Pyridopyrimidinone derivatives which are HM74A agonists
    Patent number: 7572801
    Abstract: The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: August 11, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Aurelia Conte, Henrietta Dehmlow, Uwe Grether, Nicole A. Kratochwil, Holger Kuehne, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters, Fabienne Ricklin, Stephan Roever
  • 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents
    Publication number: 20080085906
    Abstract: The present invention relates to a method of raising HDL cholesterol comprising administering to a patient in need thereof a compound of the formula wherein A, G, R1 to R8 and R17 are as defined in the description.
    Type: Application
    Filed: September 27, 2007
    Publication date: April 10, 2008
    Inventors: Mirjana Andjelkovic, Agnes Benardeau, Evelyne Chaput, Paul Hebeisen, Matthias Nettekoven, Ulrike Sander, Constantinos Panousis, Stephan Roever
  • Novel pyridopyprimidinone derivatives which are HM74A agonists
    Publication number: 20070275987
    Abstract: The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.
    Type: Application
    Filed: May 11, 2007
    Publication date: November 29, 2007
    Inventors: Aurelia Conte, Henrietta Dehmlow, Uwe Grether, Nicole A. Kratochwil, Holger Kuehne, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters, Fabienne Ricklin, Stephan Roever
  • Novel thiophene derivatives which are HM74A agonists
    Publication number: 20070161650
    Abstract: The invention is concerned with novel substituted thiophene derivatives of formula (I) wherein R1 to R8, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 12, 2007
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis
  • Novel thiophene derivatives which are HM74A agonists
    Publication number: 20070072873
    Abstract: The invention is concerned with novel substituted thiophene derivatives of formula (I) wherein R1 to R8, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: September 20, 2006
    Publication date: March 29, 2007
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis
  • Novel anthranilic acid derivatives
    Publication number: 20060281810
    Abstract: The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14 and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: June 12, 2006
    Publication date: December 14, 2006
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters